Advanced Enzyme Technologies Limited — PPTs, 22-09-2025: Investor Presentation

Advanced Enzyme Technologies Limited (AETL) reported robust Q1 FY26 performance with revenue surging 20% year-on-year to ₹185.9 Crore. Profit After Tax (PAT) climbed 16% YoY to ₹40.4 Crore, and Earnings Per Share (EPS) rose 17% to ₹3.57. While full year FY25 revenue grew modestly by 2% to ₹636.9 Crore (PAT down 2% to ₹134.0 Crore), Q1 FY26 shows strong momentum. Human Healthcare & Nutrition remains the largest revenue segment.

AETL is strategically expanding its global presence in key markets like USA, MENA, and Asia, alongside continued significant investment in R&D for new enzymes and probiotics. Recent highlights include establishing Starya Labs for independent testing and commissioning a 510kW solar power plant in 2025. The company also secured crucial food enzyme dossier approvals from EFSA and GRAS dossiers from USFDA in 2024.

Management is focused on broadening its product portfolio in animal nutrition and human probiotics, developing biocatalysis solutions for API manufacturers, and expanding its baking solutions globally to strengthen market position and tap into new opportunities.